Our Programs

Targeting Rare and Infectious Diseases

AVI BioPharma’s therapeutic development programs include lead candidates for Duchenne muscular dystrophy, hemorrhagic virus infections and influenza. We are encouraged by positive results in preclinical and clinical trials.

This page was last updated on July 31, 2010.



Research and Development Pipeline

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
DMD - Exon 51
AVI-4658
DMD - Exon 50
AVI-5038
Ebola VIrus
AVI-6002
Marburg Virus
AVI-6003
Junin Virus
AVI-7012
Influenza Therapy
AVI-7100
Dengue Virus
AVI-6006
Learn About Our Corporate Presentations Sign Up For Email Alerts